Journals / Medical Network Klinik Bilimler ve Doktor / 2003 / Cilt: 9 - Sayı: 4

Bone mineral density and urinary N-telopeptide levels in premenopausal women with thyrotoxicosis

Tirotoksikozlu premenopozal kadın hastalarda kemik mineral yoğunluğu ve üriner N-telopeptit düzeyi

Pages
401–407
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our results suggest that bone resorption is increased, and NTx, a marker of bone resorption, is directly related to the severity of thyrotoxicosis in premenopausal patients with thyrotoxicosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Thyrotoxicosis causes increases in bone resorption due to increased osteoblastic activity and indirect effects of osteoblast, sometimes leading to secondary osteoporosis.
📊
Key Findings & Data:Material and Method: 20 premenopausal patients with thyrotoxicosis are involved in the study.
💡
Conclusion & Impact:Conclusion: Our results suggest that bone resorption is increased, and NTx, a marker of bone resorption, is directly related to the severity of thyrotoxicosis in premenopausal patients with thyrotoxicosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Tirotoksikoz · Osteoporoz · Kemik yoğunluğu

Abstract

Objective: Thyrotoxicosis causes increases in bone resorption due to increased osteoblastic activity and indirect effects of osteoblast, sometimes leading to secondary osteoporosis. The aim of the study is to evaluate the changes in bone and mineral metabolism in premenopausal women with thyrotoxicosis by urinary NTx levels and to determine a possible correlation between thyroid hormone, urinary NTx levels and bone mineral densities. Material and Method: 20 premenopausal patients with thyrotoxicosis are involved in the study. Age-matched 20 euthyroid premenopausal healthy women served as the controls. Serum TSH, free T3 and free T4 levels are measured on fasting morning venous blood sample. NTx level is measured on 24 hour urine sample. Bone mineral densities of lumbar vertebrae and hip are measured in lumbar and hip region. Result: Thyrotoxic patients had lower lumbar and hip mineral densities (1.025±0.04 vs. 1.185±0.03 gr/cm2, p<0.001; and 0.890±0.04 vs. 1.031±0.03 gr/cm2, p<0.01, respectively), and higher urinary NTx level (113.00±12.97 vs. 32.94±3.25 nmolBCE/mmolCR, respectively, p<0.001) than the controls. Urinary NTx level was correlated with free T3 ands free T4 levels in thyrotoxic patients (r= 0.74, p<0.001, and r=0.63, p=0.03, respectively). However, no correlation was found between BMD and NTx. Conclusion: Our results suggest that bone resorption is increased, and NTx, a marker of bone resorption, is directly related to the severity of thyrotoxicosis in premenopausal patients with thyrotoxicosis. Evaluation of urinary NTx in the presence of bone mineral density may be helpful in early detection and prevention of bone and mineral metabolism diseases that might develop in thyrotoxicosis.

Özet

Amaç: Tirotoksikoz sendromunda kemik döngüsü (turnover) etkilenmektedir. Osteoblastik aktivite ve aynı zamanda osteoblastların indirekt etkisiyle osteoklastik kemik rezorpsiyonu artar ve oluşan kemik kaybı sekonder osteoporoza kadar ilerleyebilir. Bu çalışmanın amacı, tirotoksikozlu premenopozal kadın hastalarda kemik ve mineral metabolizma değişikliklerinin üriner N-telopeptit (NTx) düzeyi ile değerlendirmesi, kemik mineral yoğunluğu, tiroid hormon düzeyleri ve üriner NTx arasında korelasyon olup olmadığının tespitidir. Gereç ve Yöntem: Çalışmaya tirotoksikozu olan 20 premenopozal kadın hasta alındı. Kontrol grubu olarak hasta grubu ile yaşları uyumlu, herhangi bir kronik hastalığı olmayan, ötiroid 20 premenopozal sağlıklı kadın çalışmaya dahil edildi. Bulgular: Hasta grubunda kontrol grubuna göre lomber ve kalça kemik mineral yoğunluğu değerleri daha düşük iken (sırasıyla L2-L4 vertebralar 1.025±0.04'e karşı 1.185±0.03, p<0.001, total kalça 0.890±0.04'e karşı 1.031±0.03 gr/cm2 p<0.01) üriner NTx düzeyi anlamlı derecede yüksek bulundu (sırasıyla 113.00±12.97'e karşı 32.94±3.25 nmolBCE/mmolCR, p<0.001). Hasta grubunda üriner NTx düzeyi ile sT3 ve sT4 arasında istatiksel olarak anlamlı pozitif korelasyon saptandı (sırasıyla r=0.63, p=0.03); üriner NTx ile kemik mineral yoğunluğu değerleri arasında anlamlı ilişki saptanmadı. Sonuç: Sonuç olarak, verilerimiz tirotoksikozlu premenopozal kadın hastalarda kemik rezorbsiyonunu göstermekte ve kemik rezorbsiyon oranı, tirotoksikozun ciddiyeti ile doğrudan ilişkili görünmektedir. Üriner N-telopeptitin kemik mineral dansitometresi ile beraber değerlendirilmesi, tirotoksikoza bağlı gelişebilecek kemik ve mineral metabolizma hastalıklarının erken teşhisinde ve gerekli koruyucu tedbirlerin alınmasında faydalı olabilir.

🔖

Cite This Article

KUTLUTÜRK, F., ÇAKIR, B., GÜLER, S., GÜL, K., ÇULHA, C., ÖZIŞIK, D. A., YENER, G. G. (2003). Bone mineral density and urinary N-telopeptide levels in premenopausal women with thyrotoxicosis. Medical Network Klinik Bilimler ve Doktor, Cilt: 9 - Sayı: 4, 401–407. https://ajindex.com/articles/279758

References (8)

  1. Mosekilde L, Erikson EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990; 19:35-63 (Abstract). Molvalılar S. Tiroid Hastalıkları. Temel iç Hastalıkları, Ankara 1. Baskı 1996:1701-19. Gündoğan MA. Tirotoksikoz. Endokrinoloji Temel ve Klinik, Ed:S.Koloğlu, Ankara 1.Baskı 1996:247-76.
  2. Guo CY, Weetman AP, Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenapousal women on thyroxine. Clinical Endocrinology 1997; 46:301-7.
  3. Paul TL, Kerrigan J, Kelly MA. long-term L-thyroxine therapy is associated with decreased bone density in premenopausal women. JAMA 1998; 259:3137-41 (Abstract). Hanna FW, Pettit RJ, Ammari F. Effect of replacement doses of thyroxine on bone mineral density. Clinical Endocrinology 1998;48:229-34.
  4. Garton M, Reid I, Loveridge N, Robins S. Bone Mineral den­sity and metabolism in premenopausal women taking L-thyroxi­ne replacement therapy. Clinical Endocrinology 1994; 41:747-55. Franklyn JA. Long-term thyroxine treatment and bone mineral density. The Lancet, 1992; 340:9-13 (Abstract). Gam AN. Effect of thyroxine therapy on bone metabolism in substituted hypothyroid patient with normal or supressed levels of TSH. Journal of Endocr. invest 1991; 14:451 (Abstract). Schneider D, Barret-Connor E. Urinary N-Telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch intern Med 1997; 157:1241-5.
  5. Taga M, Uemura T. The effect of hormon replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of type I collagen, new markers of bone resorpti­on. Journal of Endocrinology investigation 1998; 21:154-9.
  6. Siddiqi A, Burrin JM, Noonan K, James I, Wood DF. A longitudinal study of markers of bone turnover in Graves' Disease and their value in predicting bone density. Journal of Clinical Endocrinology and Metabolism 1997; 82:753-9. Sepici V. Osteoporoz tanı ve laboratuvar yöntemleri. Osteoporoz, Ed:Y.G. Kutsal, istanbul 1998:104-18.
  7. Pantazi H, Papapetreu P. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. The Journal of Clinical Endocrinology&Metabolism 2000; 85:1099-116.
  8. Kyd PA, Vooght De K, Kerkhoff F. Clinical usefulness of biochemical resorption markers in osteoporosis. Ann Clinical Biochem 1999;36:483-91. Kutsal YG. Osteoporozda görüntüleme yöntemleri ve histomorfometri. Osteoporoz Ed:Y.G.Kutsal, 1998:81-103. Biberoğlu S. Primer Osteoporoz. Osteoporoz, Ed:S.Koloğlu, An